Skip to main content

Advertisement

SpringerLink
Log in

Bevacizumab did not reduce the risk of anemia associated with chemotherapy: an up-to-date meta-analysis

  • Review Article
  • Published:
European Journal of Clinical Pharmacology Aims and scope Submit manuscript

Abstract

Purpose

The risk of anemia due to bevacizumab-based chemotherapy has not been well described, and new randomized controlled trials (RCTs) have been reported in recent years. We therefore conducted an up-to-date meta-analysis of RCTs to fully characterize the risk of anemia with bevacizumab.

Methods

We carried out an electronic search of Medline, Embase, and The Cochrane Central Register of Controlled Trials to investigate the effects of RCTs on bevacizumab treatment on cancer patients up to October 2014, and random or fixed-effect meta-analytical models were used to assess the risk ratio (RR) of anemia due to the use of bevacizumab according to the heterogeneity of included studies.

Results

A total of 13,173 patients were included in this analysis from 18 RCTs. Among those patients receiving bevacizumab and chemotherapy, the incidences of all-grade and high-grade (grade 3 and above) anemia were 24 % (95 % confidence interval (CI) 13–41 %) and 4.0 % (95 % CI 3.0–6.0 %), respectively. Bevacizumab-containing therapy did not significantly decreased the risk of developing all-grade anemia (RR 0.872, 95 % CI 0.739–1.029, P = 0.104) and high-grade anemia (RR 0.850, 95 % CI 0.720–1.002, P = 0.053), which is not in agreement with previous meta-analysis. On subgroup analysis, we did not find significant risk differences based on bevacizumab dosage, tumor types, and concomitant drugs. When stratified by dose level, a significantly decreased risk of high-grade anemia with bevacizumab was obtained in a lower dose level (2.5 mg/kg/week, RR 0.773, 95 % CI 0.611–0.978, P = 0.031) compared to control group.

Conclusions

Bevacizumab did not significantly reduce the risk of anemia with chemotherapy in cancer patients.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Ebbers HC, van Meer PJ, Moors EH, Mantel-Teeuwisse AK, Leufkens HG, Schellekens H (2013) Measures of biosimilarity in monoclonal antibodies in oncology: the case of bevacizumab. Drug Discov Today 18:872–879. doi:10.1016/j.drudis.2013.05.004

    Article  CAS  PubMed  Google Scholar 

  2. Ferrara N, Hillan KJ, Gerber HP, Novotny W (2004) Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat Rev Drug Discov 3:391–400. doi:10.1038/nrd1381

    Article  CAS  PubMed  Google Scholar 

  3. Qi WX, Shen Z, Tang LN, Yao Y (2014) Bevacizumab increases the risk of gastrointestinal perforation in cancer patients: a meta-analysis with a focus on different subgroups. Eur J Clin Pharmacol 70:893–906. doi:10.1007/s00228-014-1687-9

    Article  CAS  PubMed  Google Scholar 

  4. Cohen MH, Gootenberg J, Keegan P, Pazdur R (2007) FDA drug approval summary: bevacizumab plus FOLFOX4 as second-line treatment of colorectal cancer. Oncologist 12:356–361. doi:10.1634/theoncologist.12-3-356

    Article  CAS  PubMed  Google Scholar 

  5. Cohen MH, Gootenberg J, Keegan P, Pazdur R (2007) FDA drug approval summary: bevacizumab (Avastin) plus Carboplatin and Paclitaxel as first-line treatment of advanced/metastatic recurrent nonsquamous non-small cell lung cancer. Oncologist 12:713–718. doi:10.1634/theoncologist.12-6-713

    Article  CAS  PubMed  Google Scholar 

  6. Friedman HS, Prados MD, Wen PY, Mikkelsen T, Schiff D, Abrey LE, Yung WK, Paleologos N, Nicholas MK, Jensen R, Vredenburgh J, Huang J, Zheng M, Cloughesy T (2009) Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol Off J Am Soc Clin Oncol 27:4733–4740. doi:10.1200/JCO.2008.19.8721

    Article  CAS  Google Scholar 

  7. Burger RA, Brady MF, Bookman MA, Fleming GF, Monk BJ, Huang H, Mannel RS, Homesley HD, Fowler J, Greer BE, Boente M, Birrer MJ, Liang SX (2011) Incorporation of bevacizumab in the primary treatment of ovarian cancer. N Engl J Med 365:2473–2483. doi:10.1056/NEJMoa1104390

    Article  CAS  PubMed  Google Scholar 

  8. Frampton JE, Keating GM (2008) Bevacizumab: in first-line treatment of advanced and/or metastatic renal cell carcinoma. BioDrugs Clin Immunotherapeutics Biopharmaceuticals Gene Ther 22:113–120

    Article  CAS  Google Scholar 

  9. Xue Y, Chen F, Zhang D, Lim S, Cao Y (2009) Tumor-derived VEGF modulates hematopoiesis. J Angiogenes Res 1:9. doi:10.1186/2040-2384-1-9

    Article  PubMed Central  PubMed  Google Scholar 

  10. Xue Y, Religa P, Cao R, Hansen AJ, Lucchini F, Jones B, Wu Y, Zhu Z, Pytowski B, Liang Y, Zhong W, Vezzoni P, Rozell B, Cao Y (2008) Anti-VEGF agents confer survival advantages to tumor-bearing mice by improving cancer-associated systemic syndrome. Proc Natl Acad Sci U S A 105:18513–18518. doi:10.1073/pnas.0807967105

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  11. Tam BY, Wei K, Rudge JS, Hoffman J, Holash J, Park SK, Yuan J, Hefner C, Chartier C, Lee JS, Jiang S, Nayak NR, Kuypers FA, Ma L, Sundram U, Wu G, Garcia JA, Schrier SL, Maher JJ, Johnson RS, Yancopoulos GD, Mulligan RC, Kuo CJ (2006) VEGF modulates erythropoiesis through regulation of adult hepatic erythropoietin synthesis. Nat Med 12:793–800. doi:10.1038/nm1428

    Article  CAS  PubMed  Google Scholar 

  12. Harshman LC, Kuo CJ, Wong BY, Vogelzang NJ, Srinivas S (2009) Increased hemoglobin associated with VEGF inhibitors in advanced renal cell carcinoma. Cancer Investig 27:851–856. doi:10.1080/07357900902744528

    Article  CAS  Google Scholar 

  13. Sher A, Wu S (2011) Anti-vascular endothelial growth factor antibody bevacizumab reduced the risk of anemia associated with chemotherapy—a meta-analysis. Acta Oncol (Stockholm, Sweden) 50:997–1005. doi:10.3109/0284186x.2011.581689

    Article  CAS  Google Scholar 

  14. Schutz FA, Jardim DL, Je Y, Choueiri TK (2011) Haematologic toxicities associated with the addition of bevacizumab in cancer patients. Eur J Cancer (Oxford, England: 1990) 47:1161–1174. doi:10.1016/j.ejca.2011.03.005

    Article  CAS  Google Scholar 

  15. Miles D, Chan A, Romieu G, Dirix LY, Cortes J, Pivot X et al (2008) Randomized, double-blind, placebo-controlled, phase III study of bevacizumab with docetaxel or docetaxel with placebo as first-line therapy for patients with locally recurrent or metastatic breast cancer (mBC):AVADO. J Clin Oncol (Meet Abstr) 26(15suppl):LBA1011

    Google Scholar 

  16. Miles DW, Chan A, Dirix LY, Cortes J, Pivot X, Tomczak P, Delozier T, Sohn JH, Provencher L, Puglisi F, Harbeck N, Steger GG, Schneeweiss A, Wardley AM, Chlistalla A, Romieu G (2010) Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer. J Clin Oncol Off J Am Soc Clin Oncol 28:3239–3247. doi:10.1200/jco.2008.21.6457

    Article  CAS  Google Scholar 

  17. White D, Kassim A, Bhaskar B, Yi J, Wamstad K, Paton VE (2013) Results from AMBER, a randomized phase 2 study of bevacizumab and bortezomib versus bortezomib in relapsed or refractory multiple myeloma. Cancer 119:339–347. doi:10.1002/cncr.27745

    Article  CAS  PubMed  Google Scholar 

  18. Cameron D, Brown J, Dent R, Jackisch C, Mackey J, Pivot X, Steger GG, Suter TM, Toi M, Parmar M, Laeufle R, Im YH, Romieu G, Harvey V, Lipatov O, Pienkowski T, Cottu P, Chan A, Im SA, Hall PS, Bubuteishvili-Pacaud L, Henschel V, Deurloo RJ, Pallaud C, Bell R (2013) Adjuvant bevacizumab-containing therapy in triple-negative breast cancer (BEATRICE): primary results of a randomised, phase 3 trial. Lancet Oncol 14:933–942. doi:10.1016/s1470-2045(13)70335-8

    Article  CAS  PubMed  Google Scholar 

  19. von Minckwitz G, Eidtmann H, Rezai M, Fasching PA, Tesch H, Eggemann H, Schrader I, Kittel K, Hanusch C, Kreienberg R, Solbach C, Gerber B, Jackisch C, Kunz G, Blohmer JU, Huober J, Hauschild M, Fehm T, Muller BM, Denkert C, Loibl S, Nekljudova V, Untch M (2012) Neoadjuvant chemotherapy and bevacizumab for HER2-negative breast cancer. N Engl J Med 366:299–309. doi:10.1056/NEJMoa1111065

    Article  Google Scholar 

  20. Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ, McQuay HJ (1996) Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 17:1–12

    Article  CAS  PubMed  Google Scholar 

  21. Choueiri TK, Schutz FA, Je Y, Rosenberg JE, Bellmunt J (2010) Risk of arterial thromboembolic events with sunitinib and sorafenib: a systematic review and meta-analysis of clinical trials. J Clin Oncol Off J Am Soc Clin Oncol 28:2280–2285. doi:10.1200/jco.2009.27.2757

    Article  CAS  Google Scholar 

  22. Miller K, Wang M, Gralow J, Dickler M, Cobleigh M, Perez EA, Shenkier T, Cella D, Davidson NE (2007) Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 357:2666–2676. doi:10.1056/NEJMoa072113

    Article  CAS  PubMed  Google Scholar 

  23. Miller KD, Chap LI, Holmes FA, Cobleigh MA, Marcom PK, Fehrenbacher L, Dickler M, Overmoyer BA, Reimann JD, Sing AP, Langmuir V, Rugo HS (2005) Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. J Clin Oncol Off J Am Soc Clin Oncol 23:792–799. doi:10.1200/jco.2005.05.098

    Article  CAS  Google Scholar 

  24. Niho S, Kunitoh H, Nokihara H, Horai T, Ichinose Y, Hida T, Yamamoto N, Kawahara M, Shinkai T, Nakagawa K, Matsui K, Negoro S, Yokoyama A, Kudoh S, Kiura K, Mori K, Okamoto H, Sakai H, Takeda K, Yokota S, Saijo N, Fukuoka M (2012) Randomized phase II study of first-line carboplatin-paclitaxel with or without bevacizumab in Japanese patients with advanced non-squamous non-small-cell lung cancer. Lung Cancer (Amst Neth) 76:362–367. doi:10.1016/j.lungcan.2011.12.005

    Article  Google Scholar 

  25. Reck M, von Pawel J, Zatloukal P, Ramlau R, Gorbounova V, Hirsh V, Leighl N, Mezger J, Archer V, Moore N, Manegold C (2009) Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAil. J Clin Oncol Off J Am Soc Clin Oncol 27:1227–1234. doi:10.1200/jco.2007.14.5466

    Article  CAS  Google Scholar 

  26. Herbst RS, O’Neill VJ, Fehrenbacher L, Belani CP, Bonomi PD, Hart L, Melnyk O, Ramies D, Lin M, Sandler A (2007) Phase II study of efficacy and safety of bevacizumab in combination with chemotherapy or erlotinib compared with chemotherapy alone for treatment of recurrent or refractory non small-cell lung cancer. J Clin Oncol Off J Am Soc Clin Oncol 25:4743–4750. doi:10.1200/jco.2007.12.3026

    Article  CAS  Google Scholar 

  27. Sandler A, Gray R, Perry MC, Brahmer J, Schiller JH, Dowlati A, Lilenbaum R, Johnson DH (2006) Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 355:2542–2550. doi:10.1056/NEJMoa061884

    Article  CAS  PubMed  Google Scholar 

  28. Rini BI, Halabi S, Rosenberg JE, Stadler WM, Vaena DA, Archer L, Atkins JN, Picus J, Czaykowski P, Dutcher J, Small EJ (2010) Phase III trial of bevacizumab plus interferon alfa versus interferon alfa monotherapy in patients with metastatic renal cell carcinoma: final results of CALGB 90206. J Clin Oncol Off J Am Soc Clin Oncol 28:2137–2143. doi:10.1200/jco.2009.26.5561

    Article  CAS  Google Scholar 

  29. Escudier B, Pluzanska A, Koralewski P, Ravaud A, Bracarda S, Szczylik C, Chevreau C, Filipek M, Melichar B, Bajetta E, Gorbunova V, Bay JO, Bodrogi I, Jagiello-Gruszfeld A, Moore N (2007) Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet 370:2103–2111. doi:10.1016/s0140-6736(07)61904-7

    Article  PubMed  Google Scholar 

  30. Kindler HL, Niedzwiecki D, Hollis D, Sutherland S, Schrag D, Hurwitz H, Innocenti F, Mulcahy MF, O’Reilly E, Wozniak TF, Picus J, Bhargava P, Mayer RJ, Schilsky RL, Goldberg RM (2010) Gemcitabine plus bevacizumab compared with gemcitabine plus placebo in patients with advanced pancreatic cancer: phase III trial of the Cancer and Leukemia Group B (CALGB 80303). J Clin Oncol Off J Am Soc Clin Oncol 28:3617–3622. doi:10.1200/jco.2010.28.1386

    Article  CAS  Google Scholar 

  31. Van Cutsem E, Vervenne WL, Bennouna J, Humblet Y, Gill S, Van Laethem JL, Verslype C, Scheithauer W, Shang A, Cosaert J, Moore MJ (2009) Phase III trial of bevacizumab in combination with gemcitabine and erlotinib in patients with metastatic pancreatic cancer. J Clin Oncol Off J Am Soc Clin Oncol 27:2231–2237. doi:10.1200/jco.2008.20.0238

    Article  Google Scholar 

  32. Guan ZZ, Xu JM, Luo RC, Feng FY, Wang LW, Shen L, Yu SY, Ba Y, Liang J, Wang D, Qin SK, Wang JJ, He J, Qi C, Xu RH (2011) Efficacy and safety of bevacizumab plus chemotherapy in Chinese patients with metastatic colorectal cancer: a randomized phase III ARTIST trial. Chin J Cancer 30:682–689. doi:10.5732/cjc.011.10188

    Article  PubMed Central  PubMed  Google Scholar 

  33. Ohtsu A, Shah MA, Van Cutsem E, Rha SY, Sawaki A, Park SR, Lim HY, Yamada Y, Wu J, Langer B, Starnawski M, Kang YK (2011) Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a randomized, double-blind, placebo-controlled phase III study. J Clin Oncol Off J Am Soc Clin Oncol 29:3968–3976. doi:10.1200/jco.2011.36.2236

    Article  CAS  Google Scholar 

  34. Kelly WK, Halabi S, Carducci M, George D, Mahoney JF, Stadler WM, Morris M, Kantoff P, Monk JP, Kaplan E, Vogelzang NJ, Small EJ (2012) Randomized, double-blind, placebo-controlled phase III trial comparing docetaxel and prednisone with or without bevacizumab in men with metastatic castration-resistant prostate cancer: CALGB 90401. J Clin Oncol Off J Am Soc Clin Oncol 30:1534–1540. doi:10.1200/jco.2011.39.4767

    Article  CAS  Google Scholar 

  35. Kindler HL, Karrison TG, Gandara DR, Lu C, Krug LM, Stevenson JP, Janne PA, Quinn DI, Koczywas MN, Brahmer JR, Albain KS, Taber DA, Armato SG 3rd, Vogelzang NJ, Chen HX, Stadler WM, Vokes EE (2012) Multicenter, double-blind, placebo-controlled, randomized phase II trial of gemcitabine/cisplatin plus bevacizumab or placebo in patients with malignant mesothelioma. J Clin Oncol Off J Am Soc Clin Oncol 30:2509–2515. doi:10.1200/jco.2011.41.5869

    Article  CAS  Google Scholar 

Download references

Conflict of interest

None

Author information

Authors and Affiliations

  1. Cardiothoracic Surgery, Huaihe Hospital, Henan University, No. 8 Baobei Road, Kaifeng, 475000, Henan, China

    Zuo-Pei Wang, Hai-Feng Zhang, Feng Zhang, Bao-Li Hu, Hai-Tao Wei & Yong-Yuan Guo

  2. Department of Orthopaedics, Qilu Hospital, Shandong University, Jinan, 250012, China

    Yong-Yuan Guo

Authors
  1. Zuo-Pei Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Hai-Feng Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Feng Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Bao-Li Hu
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Hai-Tao Wei
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Yong-Yuan Guo
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding authors

Correspondence to Hai-Tao Wei or Yong-Yuan Guo.

Electronic supplementary material

Below is the link to the electronic supplementary material.

Table S1

(DOCX 15 kb)

Table S2

(DOCX 24 kb)

Table S3

(DOCX 17 kb)

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Wang, ZP., Zhang, HF., Zhang, F. et al. Bevacizumab did not reduce the risk of anemia associated with chemotherapy: an up-to-date meta-analysis. Eur J Clin Pharmacol 71, 517–524 (2015). https://doi.org/10.1007/s00228-015-1818-y

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00228-015-1818-y

Keywords

Search

Navigation